Patent ID: 11952408
Assignee: JUNO THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 10:
11. The engineered cell of claim 10, wherein the genetic disruption comprises a mutation or deletion in a region of a TRAC or a TRBC gene that is within a coding region, wherein the coding region a) is an early coding region of the gene, b) is within exon 1 of the gene, c) is in the coding region within 500, 400, 300, 200, 100, or 50 base pairs of a start codon of the gene, or d) is within a target site sequence that is complementary to a targeting site of a guide RNA (gRNA) targeting domain having a sequence selected from any of SEQ ID NOS:1053 and 1259-1315, and/or wherein a targeting domain having a sequence selected from among SEQ ID NOS:1053 and 1259-1315 specifically hybridizes to the coding region, and/or wherein the coding region is within a target site sequence that is complementary to a targeting site of a gRNA targeting domain having a sequence selected from any of SEQ ID NOS: 1048 and 1229-1258, and/or wherein a targeting domain having a sequence selected from among SEQ ID NOS: 1048 and 1229-1258 specifically hybridizes to the coding region.